search

Active clinical trials for "Neoplasms"

Results 241-250 of 64586

A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC

CarcinomaNon-Small-Cell Lung

The goal of this phase II, open-label, single-arm study is to evaluate the efficacy and safety of induction immunotherapy and chemotherapy followed by the multidisciplinary team (MDT)-guided radiotherapy or surgery in unresectable, stage III non-small cell lung cancer.

Recruiting34 enrollment criteria

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological...

Relapsed/Refractory Chronic Lymphocytic Leukemia

An open-label, multicenter, phase Ib/II clinical trial was conducted to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of GNC-035 quad-specific antibody injection in patients with relapsed or refractory chronic lymphocytic leukemia and other hematological malignancies

Recruiting47 enrollment criteria

A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors

Advanced Digestive System Tumor

This is an open-label, multi-center, dose-escalation clinical study to evaluate the safety, feasibility, and preliminary efficacy of IMC002 in patients with CLDN18.2 positive digestive system tumors including but not limited to advanced gastric cancer, esophagogastric junction adenocarcinoma, and advanced pancreatic cancer.

Recruiting30 enrollment criteria

Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer

Solid TumorColorectal Cancer4 more

Prospective, open label, multi-dose, sequential dose escalation, single-center, Phase 1 trial

Recruiting16 enrollment criteria

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung...

CarcinomaNon-Small-Cell Lung

This is a single arm, multi-center clinical trial. Target population is advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients with Programmed Cell Death Ligand 1 (PD-L1) negative, aiming to evaluate the efficacy and safety of the combination therapy of Cadonilimab and chemotherapy. Cadonilimab is a PD-1/CTLA-4 bi-specific antibody.

Recruiting23 enrollment criteria

Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

GliomaGlioma7 more

This single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.

Recruiting29 enrollment criteria

Randomized Evaluation of Machine Learning Assisted Radiation Treatment Planning vs Standard Radiation...

Cancer Head NeckCancer2 more

The purpose of this study is to determine the magnitude of clinical benefit achieved through machine learning assisted radiation treatment planning (MLAP) on post-treatment clinical outcomes such as acute toxicity and patient reported outcomes.

Recruiting8 enrollment criteria

Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer...

Locally Advanced Rectal Cancer

This is an open-label, single-arm study to investigate the efficacy and safety of AK104 (an Anti-PD1 and Anti-CTLA4 Bispecific Antibody) and neoadjuvant chemoradiotherapy in patients with pMMR/MSS locally advanced rectal cancer.

Recruiting23 enrollment criteria

Effect of Music Prehabilitation on Preoperative Anxiety Before Surgery

Cancer of ColonSurgery1 more

The goal of this multicenter randomized controlled trial is to investigate the effect of music prehabilitation on preoperative anxiety in patients undergoing elective oncological colorectal resection. Patients will be asked to listen to music three times a day starting one week before day of surgery. Anxiety levels will be compared with the control group that is not explicitly instructed to listen to music by using validated questionnaires

Recruiting16 enrollment criteria

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

GlioblastomaIDH-wildtype4 more

The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.

Recruiting14 enrollment criteria
1...242526...6459

Need Help? Contact our team!


We'll reach out to this number within 24 hrs